Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 10, 2025
Reporting Period: Single event date (November 10, 2025)
Business Context: The filing serves as a Regulation FD disclosure to furnish an investor presentation slide deck intended for use in company presentations.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of an exhibit (Investor Presentation) and does not contain audited financial statements or specific financial data points within the text provided.
Material Changes
No material changes to financial performance or operations are reported in this specific filing text. The document solely announces the availability of an investor presentation deck.
Guidance, Outlook, and Risks
- Management Commentary: The Company has prepared a slide deck for investor presentations, furnished as Exhibit 99.1.
- Legal Status of Information: The information in Item 7.01 and Exhibit 99.1 is furnished and shall not be deemed "filed" under Section 18 of the Exchange Act. It is not subject to the liabilities of that section and shall not be incorporated by reference into any other filings.
- Risks and Contingencies: No specific risks or contingencies are detailed in the text of this 8-K.
Investor Verification Checklist
- Review Exhibit 99.1 (Investor Presentation) for detailed financial data, clinical updates, and strategic outlook, as the 8-K text itself contains no such figures.
- Verify the legal disclaimer regarding the non-filed status of the presentation materials to understand the liability limitations.
- Confirm the signatory details: David Moss, Chief Executive Officer, signed the report on November 10, 2025.